ProKidney Corp. (PROK) shares are experiencing a steep 5.02% pre-market plunge on Friday, extending the previous day's losses. This continued downward trend comes in the wake of a bearish analyst report that has shaken investor confidence in the biotechnology company.

The sell-off appears to be primarily driven by Bank of America Securities' reiterated Sell rating on ProKidney stock. Analyst Jason Gerberry maintained his pessimistic stance on the company and set a remarkably low price target of $1.00. This grim outlook from a major financial institution has evidently spooked investors, leading to a significant 5.41% drop during Thursday's regular trading session and continuing to impact the stock in pre-market trading.

The reaffirmation of the Sell rating and the strikingly low price target could have far-reaching implications for ProKidney Corp. It may prompt increased scrutiny of the company's business model, financial health, and growth prospects. As the market digests this negative sentiment, ProKidney may face challenges in maintaining investor confidence and may need to present a robust strategy to counter the bearish outlook and stabilize its stock price in the coming trading sessions.